This webinar will detail a comprehensive strategy that a lab has put in place to evaluate NGS oncology assays for genomic tumor profiling of plasma and tissue samples.
The growing adoption of next-generation sequencing (NGS) technologies is enabling many labs to perform NGS-based tumor profiling inhouse. Today, genomic tumor profiling can be accomplished using DNA extracted from tumor tissue samples, as well as by liquid biopsy approaches using circulating tumor DNA (ctDNA) in plasma samples. The question of what labs need to consider when choosing the right solution for their research needs is of great interest.
In this webinar, Dr. Shelly Gunn, Chief Medical Officer of ResearchDx, will present an overview of their lab’s approach to establishing optimized ctDNA and formalin-fixed, paraffin-embedded (FFPE) tissue workflows for in-house clinical research testing. Dr. Gunn’s presentation will:
- Describe the process of implementing new NGS tumor tissue and ctDNA oncology assays, including learnings from optimizing both ctDNA and FFPE tissue workflows;
- Discuss areas that are important for achieving high technical performance and accurate results, such as QC methods, barcoding, and hybrid capture vs. amplicon technology;
- Summarize areas of research where the combination of these technologies could be applied.
The AVENIO ctDNA Analysis Kits and AVENIO Tumor Tissue Analysis Kits are for research use only, and not for use in diagnostic procedures.
AVENIO is a trademark of Roche.